G1 Therapeutics, Inc.
Simbolis: GTHX
NASDAQ
4.44
USDRinkos kaina šiandien
-7.4160
P/E santykis
-0.3307
PEG koeficientas
232.23M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
G1 Therapeutics, Inc. (GTHX) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 345.99 | 82.2 | 145.1 | 221.2 | ||||||||||
balance-sheet.row.short-term-investments | 185.28 | 49.9 | 50.5 | 0 | ||||||||||
balance-sheet.row.net-receivables | 46.78 | 12.7 | 11.1 | 5.7 | ||||||||||
balance-sheet.row.inventory | 54.08 | 12.4 | 16.2 | 3.5 | ||||||||||
balance-sheet.row.other-current-assets | 30.42 | 7.6 | 7.1 | 13.2 | ||||||||||
balance-sheet.row.total-current-assets | 477.33 | 114.9 | 179.5 | 243.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 26.32 | 6.4 | 8 | 9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0.62 | 0.2 | 0.3 | 0.3 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.28 | 0 | 0.3 | 1.2 | ||||||||||
balance-sheet.row.total-non-current-assets | 27.23 | 6.6 | 8.5 | 10.5 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 504.55 | 121.5 | 188 | 254.1 | ||||||||||
balance-sheet.row.account-payables | 22.2 | 4 | 7.4 | 2.9 | ||||||||||
balance-sheet.row.short-term-debt | 31.9 | 1.3 | 1.1 | 1.1 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 116.16 | 51.6 | 82.6 | 81.9 | ||||||||||
Deferred Revenue Non Current | 2 | 0.5 | 1 | 1 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -46.6 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 73.94 | 23.8 | 27 | 23.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 210.97 | 56.4 | 83.6 | 82.9 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 18.01 | 4.3 | 6.8 | 7.9 | ||||||||||
balance-sheet.row.total-liab | 340.86 | 86.2 | 119.2 | 110.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -3090.2 | -780 | -732 | -584.5 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 2441.74 | 815.4 | 800.8 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -307.57 | 121.5 | 188 | -473.9 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -307.57 | - | - | - | ||||||||||
Total Investments | 185.47 | 50.1 | 50.5 | 0.3 | ||||||||||
balance-sheet.row.total-debt | 127.72 | 57.2 | 83.8 | 83.1 | ||||||||||
balance-sheet.row.net-debt | -74.71 | 24.9 | -10.8 | -138.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -30.59 | -48 | -147.6 | -148.4 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0.5 | 0.5 | 0.5 | 0.5 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 1.2 | 0 | 0.6 | ||||||||||
cash-flows.row.stock-based-compensation | 10.67 | 14.5 | 20.6 | 22.3 | ||||||||||
cash-flows.row.change-in-working-capital | 1.14 | -5.2 | -5.3 | -8.8 | ||||||||||
cash-flows.row.account-receivables | 4.37 | -1.6 | -5.4 | -5.5 | ||||||||||
cash-flows.row.inventory | 3 | 3.7 | -12.7 | -3.5 | ||||||||||
cash-flows.row.account-payables | -0.37 | -3.4 | 4.4 | -0.7 | ||||||||||
cash-flows.row.other-working-capital | -4.26 | -4 | 8.4 | 0.8 | ||||||||||
cash-flows.row.other-non-cash-items | 9.12 | -1.4 | 3.1 | 1.7 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -18.18 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 50 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -116.81 | -124.7 | -65 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 122 | 127.5 | 15 | 0 | ||||||||||
cash-flows.row.other-investing-activites | -0.1 | 0 | -50 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 5.19 | 2.8 | -50.5 | 0 | ||||||||||
cash-flows.row.debt-repayment | -26.69 | -26.7 | 0 | -53.6 | ||||||||||
cash-flows.row.common-stock-issued | -0.01 | -0.2 | 52.4 | 86.4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -8.76 | -0.3 | 0.1 | 113.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -35.42 | -26.9 | 52.5 | 145.9 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -48.41 | -62.4 | -126.7 | 13.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 161.52 | 32.3 | 94.9 | 221.6 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 209.93 | 94.7 | 221.6 | 207.8 | ||||||||||
cash-flows.row.operating-cash-flow | -18.18 | -38.3 | -128.6 | -132.1 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | -18.18 | -38.3 | -129.1 | -132.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 84.04 | 82.5 | 51.3 | 31.5 | ||||||||||
income-statement-row.row.cost-of-revenue | 6.82 | 7.2 | 3.7 | 2 | ||||||||||
income-statement-row.row.gross-profit | 77.23 | 75.3 | 47.6 | 29.5 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 35.55 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.operating-expenses | 102.6 | 114.8 | 183.7 | 171.9 | ||||||||||
income-statement-row.row.cost-and-expenses | 106.34 | 122 | 187.5 | 173.9 | ||||||||||
income-statement-row.row.interest-income | 2.04 | 2.5 | 0.7 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.total-operating-expenses | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0.51 | 0.5 | 1.3 | -0.3 | ||||||||||
income-statement-row.row.ebitda-caps | -21.23 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -22.83 | -39.5 | -136.2 | -142.5 | ||||||||||
income-statement-row.row.income-before-tax | -27.48 | -44.9 | -145.9 | -147.4 | ||||||||||
income-statement-row.row.income-tax-expense | 3.12 | 3.1 | 1.7 | 0.9 | ||||||||||
income-statement-row.row.net-income | -30.59 | -48 | -147.6 | -148.4 |
Dažnai užduodami klausimai
Kas yra G1 Therapeutics, Inc. (GTHX) bendras turtas?
G1 Therapeutics, Inc. (GTHX) bendras turtas yra 121540000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 29349000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.919.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.356.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.364.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.272.
Kas yra G1 Therapeutics, Inc. (GTHX) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -47967000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 57173000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 114843000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 19887000.000.